---
title: "Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414681.md"
description: "Genprex announced preclinical data at ASGCT showing that its Pdx1/MafA gene therapy (PM) effectively reversed hyperglycemia in Type 2 diabetic mice. Key findings include restored insulin secretion and improved β-cell function in PM-treated islets. Both β-cell–specific and global PM delivery methods enhanced glucose control and β-cell maturation. The company suggests that the pancreatic delivery technique is feasible for human application, indicating potential for long-term glycemic control."
datetime: "2026-05-14T12:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414681.md)
  - [en](https://longbridge.com/en/news/286414681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414681.md)
---

# Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT

**Genprex announced preclinical data showing its Pdx1/MafA gene therapy (PM) reversed hyperglycemia in Type 2 diabetic mouse models.**

**Key Highlights:**

-   Researchers presented at ASGCT that AAV-delivered PM (GPX-002) reversed hyperglycemia in high-fat-diet T2D mice, indicating efficacy.
-   Ex-vivo GSIS and EM showed PM-treated islets had restored insulin secretion, increased mature insulin granules, and improved β-cell function.
-   β-cell–specific (RIP) and global (CMV) PM delivery both improved glucose control and promoted β-cell maturation per transcriptomic analysis.
-   Company says pancreatic delivery via endoscopic retrograde technique is technically translatable to humans, supporting potential long-term glycemic control development.

Original SEC Filing: Genprex, Inc. \[ GNPX \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md)